# US 2025/0367174 A1 · Bet inhibitors as a treatment for myelofibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367174 A1
- Document ID: US20250367174A1
- Status: Published application
- Kind: A1
- Application number: 19/236,392
- Filed: 2025-06-12
- Published: 2025-12-04
- Earliest claimed: 2021-02-25
- Assignees: Impact Biomedicines, Inc.
- Applicants: Impact Biomedicines, Inc.
- Inventors: Ida ARONCHIK; Roxxana Valeria BELTRAN VALENCIA; Maria Soraya CARRANCIO ANTON; Henry H. CHANG; Shodeinde COKER; Sharmila DAS; Ellen Hope FILVAROFF; Carla GUARINOS MARHUENDA; Bishoy HANNA; Yu LIU; Zariana NIKOLOVA; Oriana ESPOSITO
- Web page: https://patentgrep.com/patent/US20250367174A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in patients in need thereof. The methods comprise administering to a patient in need a BET (bromodomain and extra-terminal protein) inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with one or more JAK inhibitors. Also provided are medicaments for use in treating cancer.

## Claims

### Claim 1

A method of treating a hematological malignancy in a subject in need thereof, the method comprising administering to the subject:
a compound of formula (I):
or a pharmaceutically acceptable salt thereof; and
a compound of formula (II):
or a pharmaceutically acceptable salt and/or solvate thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (II), or the pharmaceutically acceptable salt and/or solvate thereof, are administered concurrently.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (II), or the pharmaceutically acceptable salt and/or solvate thereof, are administered sequentially.

### Claim 4 (depends on 1)

The method of claim 1, wherein the administration of the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (II), or the pharmaceutically acceptable salt and/or solvate thereof, provides a synergistic effect.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (II), or the pharmaceutically acceptable salt and/or solvate thereof, are each administered orally.

### Claim 6 (depends on 1)

The method of claim 1, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is administered at a dose of from about 0.1 mg to about 10 mg.

### Claim 7 (depends on 1)

The method of claim 1, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is administered at a dose of from about 0.25 mg to about 4.5 mg.

### Claim 8 (depends on 1)

The method of claim 1, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is administered at a dose of 0.25 mg, 0.5 mg, 0.75 mg, 1.0 mg, 1.25 mg, 1.5 mg, or 2.0 mg.

### Claim 9 (depends on 1)

The method of claim 1, wherein the compound of formula (II), or the pharmaceutically acceptable salt and/or solvate thereof, is administered in an amount of from about 50 mg to about 500 mg.

### Claim 10 (depends on 1)

The method of claim 1, wherein the compound of formula (II), or the pharmaceutically acceptable salt and/or solvate thereof, is administered in an amount of about 400 mg.

### Claim 11 (depends on 1)

The method of claim 1, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is administered once daily.

### Claim 12 (depends on 1)

The method of claim 1, wherein the compound of formula (II), or the pharmaceutically acceptable salt thereof, is administered once daily.

### Claim 13 (depends on 1)

The method of claim 1, wherein the compound of formula (II) or a pharmaceutically acceptable salt and/or hydrate thereof is administered.

### Claim 14 (depends on 1)

The method of claim 1, wherein the dihydrochloride monohydrate of the compound of formula (II) is administered.

### Claim 15

A method of treating a hematological malignancy in a subject in need thereof, the method comprising administering to the subject:
a compound of formula (I):
or a pharmaceutically acceptable salt thereof; and
a compound of formula (III):
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (III), or the pharmaceutically acceptable salt and/thereof, are administered concurrently.

### Claim 17 (depends on 15)

The method of claim 15, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (III), or the pharmaceutically acceptable salt thereof, are administered sequentially.

### Claim 18 (depends on 15)

The method of claim 15, wherein the administration of the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (III), or the pharmaceutically acceptable salt thereof, provides a synergistic effect.

### Claim 19 (depends on 15)

The method of claim 15, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (III), or the pharmaceutically acceptable salt thereof, are each administered orally.

### Claim 20 (depends on 15)

The method of claim 15, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is administered at a dose of from about 0.1 mg to about 10 mg.

### Claim 21 (depends on 15)

The method of claim 15, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is administered at a dose of from about 0.25 mg to about 4.5 mg.

### Claim 22 (depends on 15)

The method of claim 15, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is administered at a dose of 1.25 mg, 2.0 mg, 3.0 mg, 4.0 mg, or 4.5 mg.

### Claim 23 (depends on 15)

The method of claim 15, wherein the compound of formula (III), or the pharmaceutically acceptable salt thereof, is administered in an amount of from about 5 mg to about 50 mg.

### Claim 24 (depends on 15)

The method of claim 15, wherein the compound of formula (III), or the pharmaceutically acceptable salt thereof, is administered in an amount of about 15 mg.

### Claim 25 (depends on 15)

The method of claim 15, wherein the dose of the compound of formula (III), or the pharmaceutically acceptable salt thereof, is administered twice a day.

### Claim 26 (depends on 15)

The method of claim 15, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is administered once daily.

### Claim 27 (depends on 15)

The method of claim 15, wherein the dose of the compound of formula (I), or the pharmaceutically acceptable salt thereof, is administered twice a day.

### Claim 28 (depends on 15)

The method of claim 15, wherein the phosphoric acid salt of the compound of formula (III) is administered.

### Claim 29

A method of treating a hematological malignancy in a subject in need thereof, the method comprising administering to the subject a compound of formula (I):
or a pharmaceutically acceptable salt thereof.

### Claim at position 30

-48. (canceled)
